Creative Enzymes Launches AI Platform to Revolutionize Biocatalysis

Creative Enzymes, a global leader in enzyme technology, has launched an AI-integrated platform to accelerate biocatalyst development, addressing a critical bottleneck in biomanufacturing. The platform combines computational enzyme engineering with practical process development to deliver AI-Driven Biocatalysis Solutions that are both predictable in silico and robust at industrial scale. Traditional methods often struggle with the speed required for iterative product development, but AI brings three key advantages: predicting optimal enzyme candidates, designing enzymes constrained by process parameters, and using molecular features to forecast performance. This reduces R&D costs by minimizing experimental testing and lowers the risk of process failure by identifying suitable biocatalysts earlier. Additionally, it enables access to molecules previously inaccessible to enzymatic conversion, opening new product opportunities.

The platform is structured into three specialized service modules. The first, AI-driven biocatalyst discovery and engineering, spans the entire value chain from target reaction analysis to scale-up characterization, reducing the design-build-test-learn cycle from 12–24 months to 8–12 months for moderately complex targets. The second, AI-Driven Industrial Biocatalysis, focuses on bridging lab-scale and commercial production by optimizing substrate concentration, cofactor regeneration, and immobilization, while providing complete technology transfer packages. The third, AI-Driven Green Biocatalysis, emphasizes sustainability by identifying efficient enzymes that minimize solvent use, energy consumption, and waste, aligning with corporate environmental goals.

The platform's effectiveness is demonstrated through a case study on transaminase engineering for sitagliptin production. Using a 6D protein engineering framework with 1.39 million structural fragments, AI selected five transaminase variants with nine mutations each, achieving high solubility and catalytic stability at 7-liter fermentation scale. These enzymes converted prochiral ketones to sitagliptin with over 99% enantiomeric purity and up to 89% conversion during scale-up. Currently, AI biocatalysis is making the biggest impact in pharmaceuticals for chiral intermediate synthesis and hazardous reagent replacement, with growing adoption in agrochemicals for toxicology refinement, food for cleaner labels, and fine chemicals for high-value conversions and sustainable processes.